Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANGEA: Gemcitabine, Erlotinib and Nab-paclitaxel in Advanced Pancreatic Adenocarcinoma
NCT06483555Phase 2Recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Feb 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of erlotinib in pancreatic adenocarcinoma (PDAC) (4 arms), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoints: Adverse Events per Common Terminology Criteria for Adverse Events (NCI-CTCAE) at 28 days, Dose-limiting toxicity at 28 days and 2 more. Started Feb 2025; status: recruiting.
02
Drugs
erlotinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06483555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06483555.